Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases Dec 19, 2024 02:30AM
Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases Dec 19, 2024 02:30AM
Astellas Announces Sponsored Research Agreement with UMass Chan Medical School Jun 20, 2024 08:00AM
FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA® (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children Mar 11, 2024 09:00AM
Astellas Names Michael Petroutsas as Head of US Commercial Feb 22, 2024 10:15AM
View Older Stories

Feb 15, 2024 06:30PM Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics
Dec 8, 2023 01:18PM FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis
Oct 22, 2023 10:30AM Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Lin
Sep 22, 2023 05:00AM PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in
Aug 10, 2023 08:35AM U.S. FDA Accepts Astellas' sNDA for CRESEMBA® (isavuconazonium sulfate) in Children
Aug 7, 2023 09:00AM Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy
Jul 18, 2023 09:00AM Astellas and Eko Health Announce Agreement to Incorporate Next Generation Eko CORE 500™ Digital Stethoscope into Z1608, an Innovative Solution Under Development for Heart Failure Patients Built on W
Apr 3, 2023 05:00PM FDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer
Apr 3, 2023 05:00PM FDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer
Mar 28, 2023 08:02PM Astellas and Roche Diabetes Care Japan ink partnership agreement to develop and commercialize integrated diabetes self-management solution with BlueStar®
Mar 9, 2023 06:30PM Astellas and Seagen Announce China's National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic Uroth
Jan 9, 2023 07:00AM Twist Bioscience and Astellas Enter into Multitarget Antibody Discovery Research Collaboration
Dec 21, 2022 08:00PM Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
Dec 20, 2022 06:45AM Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advance
Dec 20, 2022 06:45AM Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of
Sep 12, 2022 08:55AM Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urotheli
Jul 26, 2022 04:00AM Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer
Jul 26, 2022 04:00AM Astellas and Seagen Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer
Jul 5, 2022 03:00AM Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss
Jun 27, 2022 07:31PM Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)
Jun 27, 2022 07:30PM Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)
Apr 13, 2022 11:45AM European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer
Feb 28, 2022 08:00AM Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
Feb 14, 2022 05:00PM Seagen and Astellas Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy
Feb 14, 2022 05:00PM Astellas and Seagen Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy
Dec 17, 2021 06:40AM Astellas, Seagen (SGEN) Receive Positive CHMP Opinion for PADCEV in Locally Advanced or Metastatic Urothelial Cancer
Dec 17, 2021 06:40AM Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
Dec 17, 2021 06:40AM Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
Oct 12, 2021 08:00AM Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) With Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
Oct 12, 2021 08:00AM Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) with Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
Sep 28, 2021 01:24PM Astellas Recognized Consistently Among Top Companies for Working Parents
Sep 27, 2021 03:00AM Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
Sep 27, 2021 03:00AM Japan's MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
Jul 9, 2021 02:12PM Astellas, Seagen (SGEN) Announce U.S. FDA Grants Regular Approval and Expands Indication for PADCEV for Patients with Locally Advanced or Metastatic Urothelial Cancer
Jul 9, 2021 02:10PM U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer
Jul 9, 2021 02:10PM U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer
May 19, 2021 05:21PM Seagen (SGEN) and Astellas Pharma Inc. Report Updated Results from Two Trials of PADCEV (enfortumab vedotin-ejfv)
May 19, 2021 05:04PM Astellas and Seagen Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemothe
May 19, 2021 05:00PM Seagen and Astellas Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemothe
Apr 19, 2021 08:04AM Astellas and Seagen (SGEN) Announce U.S. FDA Acceptance of Two SBLAs for PADCEV in Locally Advanced or Metastatic Urothelial Cancer
Apr 19, 2021 08:00AM Astellas and Seagen Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
Feb 18, 2021 08:03AM Astellas and Seagen (SGEN) Announce Submission of Two sBLA to U.S. FDA for PADCEV in Locally Advanced or Metastatic Urothelial Cancer
Feb 18, 2021 08:00AM Seagen and Astellas Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
Feb 18, 2021 08:00AM Astellas and Seagen Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
Feb 12, 2021 02:16PM Astellas and Seagen (SGEN) Announce Presentation of Results from PADCEV Pivotal Trial in Patients with Previously Treated Advanced UC Who Were Ineligible for Cisplatin Chemotherapy
Feb 12, 2021 02:15PM Seagen and Astellas Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer
Feb 12, 2021 02:15PM Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer
Feb 12, 2021 02:15PM Seagen and Astellas Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cispla
Feb 12, 2021 02:15PM Astellas and Seagen Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cispla
Jan 28, 2021 01:28PM Astellas Achieves 100% Score on Corporate Equality Index for Seventh Consecutive Year
View Older Stories